{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:49:23Z","timestamp":1794707363316,"version":"4.9.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to evaluate the effects of GLP-1 receptor agonists (GLP-1RA) on symptom burden and opioid use in patients with fibromyalgia using real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX Research Network. Patients with fibromyalgia (\u22652 diagnostic encounters) were divided into two groups: those with and without \u22652 prescriptions for GLP-1RA. Propensity score matching at a 1:1 ratio for age, sex and key comorbidities, including diabetes mellitus, obesity, osteoarthritis, inflammatory arthritis, ischemic heart disease, sleep disorders, migraine and medication use, was performed. Outcomes were assessed over a five-year follow-up period. This included opioid use, diagnostic codes for pain, fatigue and disability, body mass index and haemoglobin A1C. Statistical analysis included odds ratios, risk differences and t tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After propensity score matching, there were 48\u2009025 patients in each cohort. Baseline characteristics were well matched, though BMI and Haemoglobin A1c were higher in the GLP-1RA cohort than in non-GLP-1RA users. GLP-1RA use was associated with significantly reduced odds of opioid prescription (OR 0.65), pain diagnostic codes (OR 0.79) and fatigue diagnostic codes (OR 0.68) (all P\u2009&amp;lt;\u20090.001). There was no significant difference in disability-related diagnostic codes. BMI and HbA1C remained higher in patients on GLP-1RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RA use was associated with reduced opioid prescription and a reduction in the use of ICD-10 codes related to fibromyalgia, potentially reflecting lower symptom burden. Further studies using validated outcome measures are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag033","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:53:01Z","timestamp":1769086381000},"source":"Crossref","is-referenced-by-count":8,"title":["Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform"],"prefix":"10.1093","volume":"65","author":[{"given":"Nouran","family":"Eshak","sequence":"first","affiliation":[{"name":"Rheumatology Department, Mayo Clinic , Scottsdale, AZ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-4208","authenticated-orcid":false,"given":"Anushka","family":"Irani","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Mayo Clinic , Jacksonville, FL,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-1534","authenticated-orcid":false,"given":"Megan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Mayo Clinic , Scottsdale, AZ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026020706015912800_keag033-B1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2026020706015912800_keag033-B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-025-01979-4","article-title":"Advances in GLP-1 receptor agonists for pain treatment and their future potential","volume":"26","author":"He","year":"2025","journal-title":"J Headache Pain"},{"key":"2026020706015912800_keag033-B3","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","article-title":"Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity","volume":"34","author":"Gong","year":"2014","journal-title":"J Neurosci"},{"key":"2026020706015912800_keag033-B4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s10194-021-01302-x","article-title":"Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation","volume":"22","author":"Jing","year":"2021","journal-title":"J Headache Pain"},{"key":"2026020706015912800_keag033-B5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11481-025-10196-4","article-title":"Novel trajectories towards possible effects of semaglutide for amelioration of reserpine-induced fibromyalgia in rats: contribution of cAMP\/PKA\/p-CREB and M1\/M2 microglia polarization","volume":"20","author":"Shafiek","year":"2025","journal-title":"J Neuroimmune Pharmacol"},{"key":"2026020706015912800_keag033-B6","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/rheumatology\/keae707","article-title":"Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews","volume":"64","author":"Moore","year":"2025","journal-title":"Rheumatology"},{"key":"2026020706015912800_keag033-B7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.amjmed.2011.05.031","article-title":"Opioid use, misuse, and abuse in patients labeled as fibromyalgia","volume":"124","author":"Fitzcharles","year":"2011","journal-title":"Am J Med"},{"key":"2026020706015912800_keag033-B8","doi-asserted-by":"crossref","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026020706015912800_keag033-B9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s11325-023-02831-2","article-title":"The impact of fibromyalgia syndrome on obstructive sleep apnea syndrome in terms of pain threshold, daytime symptoms, anxiety, depression, disease severity, and sleep quality: a polysomnographic study","volume":"27","author":"Cigdem Karacay","year":"2023","journal-title":"Sleep Breath"},{"key":"2026020706015912800_keag033-B10","doi-asserted-by":"crossref","first-page":"1301944","DOI":"10.3389\/fmed.2023.1301944","article-title":"A retrospective analysis of the prevalence and impact of associated comorbidities on fibromyalgia outcomes in a tertiary care center","volume":"10","author":"Rivera","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026020706015912800_keag033-B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-025-01979-4","article-title":"Advances in GLP-1 receptor agonists for pain treatment and their future potential","volume":"26","author":"He","year":"2025","journal-title":"J Headache Pain"},{"key":"2026020706015912800_keag033-B12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12891-024-07263-x","article-title":"Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center","volume":"25","author":"Rivera","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"2026020706015912800_keag033-B13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/j.pain.0000000000002500","article-title":"Efficacy of nonpharmacological interventions for individual features of fibromyalgia: a systematic review and meta-analysis of randomised controlled trials","volume":"163","author":"Kundakci","year":"2022","journal-title":"Pain"},{"key":"2026020706015912800_keag033-B14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.23183","article-title":"Performance of the patient-reported outcomes measurement information system 29-item profile in rheumatoid arthritis, osteoarthritis, fibromyalgia, and systemic lupus erythematosus","volume":"69","author":"Katz","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020706015912800_keag033-B15","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00125-023-05962-z","article-title":"Socioeconomic aspects of incretin-based therapy","volume":"66","author":"Karagiannis","year":"2023","journal-title":"Diabetologia"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag033\/66564692\/keag033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag033\/66564692\/keag033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag033\/66564692\/keag033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:02:06Z","timestamp":1770462126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag033\/8440157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag033","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,29]]},"article-number":"keag033"}}